IL4 and familial hyperaldosteronism: Altogether, iPCSK9 therapy notably reduces LDLc and plasma IL-4 and MCP-1 levels, exhibiting subclinical anti-inflammatory and atherogenic effects, and indicating potential benefits for clinical outcomes in population with SR-FH.